Indian Single center retrospective study of 28 children ≤18 yrs tested w/ 18F-FDG-PET/MR for pyrexia (PUO). 25% Dx w/ pre-stenotic TAKayasu (mean 13.9 yrs), & 20/21 alternative Dxs. All had Sxs & high ESR/CRP; all Rx w/ GC & MMF, 3 w/ biologics https://t.co/6trs1WssjW https://t.co/EOPIarRhY5

It’s almost time. 🔥 Registration for RheumNow Live 2027 opens OCTOBER 1. Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice. 📅 Jan 30–31, 2027 📍 Dallas + Online https://t.co/Ju0zzYX8Tl

Prescribing New GLP-1-Based Therapies https://t.co/cpxyxBMZ8s https://t.co/9JXmlW2Lj6

New report shows Median total cash compensation increased across all seven specialty groups in 2026; adult medical rose 7.2% - Rheumatology led one-year pay growth at 10.4% https://t.co/iuonfJRsf6 https://t.co/zybCZeNV5I

Early RA Referral Clinics Work (9.18.2026) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/ofGKCCNQnE https://t.co/fn0L4goAMT https://t.co/F8QKs7261x

QD Clinic: GLP-1s and History of Thyroid Cancer? Daric Mueller, PA-C, St. Clair Shores, MI, presents this case as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/rhsUNVIdQ4 https://t.co/mjHEWNIGqU

QD Clinic: Bariatric Surgery "Curing" Arthritis? Dr. Richard Conway, Dublin, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/YwtSkroMta https://t.co/tl8eSrvGhq

Obesity in Rheumatic Diseases: More than just a Comorbidity https://t.co/0QJ188HYSm https://t.co/3L09m2cowl

Metabolomic/proteomics w/ cardiac MRI & longitudinal outcomes in 488079 UK Biobank pts shows chronic systemic inflammation assoc w/ reduced LV volumes, incr CV risk (cytokines, GFs, IL-1, TNF as potential mediators) https://t.co/3woGOttKHz https://t.co/eJLkPyJe6U

Obesity and Gout: An Old Relationship with New Thoughts https://t.co/T71u9Ta4NS https://t.co/B7vUVqIBQE

🚨 Registration opens October 1! RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting. 📍 Dallas + Online 📅 January 30–31, 2027 🎓 High-impact CME. Expert faculty. Real-world rheumatology. The rheumatology meeting that sets the tone for the year ahead. https://t.co/PFZ37DlTQe

Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 https://t.co/GlNpsPBwtS https://t.co/FJ6B5E5CWy

FORWARD is a Phase 4, OL trial in 51 refractory uncontrolled gout pts Rx w/ MTX plus higher doses pegloticase (16 or 30mg) IV q4wk. At 24-wk Responses similar 68% or 73%. ~31% of responders later had SUA >6. Confusing anti-Drug Ab results in this trial?? https://t.co/udjE7sXDm5 https://t.co/F8VGDAyJzb

Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ https://t.co/EdAqXfsjW0

Single center, DBRPCT of tofacitinib 11 mg/d vs PBO in 100 knee OA pts (KL Gr 1-2); At wk 12 there was NO significant differences betw groups in VAS Pain, or other outcomes-WOMAC, Oxford Knee Score, EQ-5D-5L, analgesic use https://t.co/VDtgY7hTm4 https://t.co/PveouQbI8r